Aspirin does not lower CVD risk

Taking aspirin does not appear to reduce the risk of cardiovascular events in patients with type-2 diabetes, according to Japanese research.

Previous studies on the use of aspirin for the primary prevention of cardiovascular disease (CVD) have been conflicting, but Joint British Societies guidance continues to recommend aspirin use for primary prevention of MI and strokes in diabetics.

This latest study involved 2,539 patients, aged 30-85, who had type-2 diabetes and no history of atherosclerosis.

Patients were randomly assigned to receive low-dose aspirin, 81-100mg, or placebo, and followed up for an average of 4.3 years.

Overall, 154 people went on to develop atherosclerosis during the study.

A total of 68 patients in the aspirin group developed atherosclerosis compared with 86 in the placebo group.

However, this was found not to be statistically significant.

Lead researcher Professor Hisao Ogawa, from Kumamato University in Japan, said that the findings showed that aspirin use did not reduce the risk of CVD. The findings echo UK research published last month (GP, 31 October).

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Follow Us: